TACE联合卡瑞利珠单抗与阿帕替尼治疗不可切除肝细胞癌的随机II期试验
该随机II期试验纳入不可切除肝细胞癌(BCLC A-C期无肝外转移、Child-Pugh A级)患者200例,1:1随机接受TACE联合卡瑞利珠单抗及阿帕替尼(TACE-C-R)或单纯TACE。联合组≥3级治疗相关不良事件发生率为74.5%,单纯TACE组为22.3%。
要点
- TACE联合卡瑞利珠单抗及阿帕替尼显著延长不可切除HCC的PFS(10.8 vs 3.2个月)。
- 联合组≥3级治疗相关不良事件发生率74.5%,以AST/ALT升高最常见。
- 总生存数据尚未成熟,需继续随访。
核心结论
- 在不可切除肝细胞癌患者中,TACE联合卡瑞利珠单抗及阿帕替尼较单纯TACE显著改善复合标准PFS,安全性可控。
研究设计与样本
- 随机II期试验,纳入不可切除HCC(BCLC A-C期无肝外转移、Child-Pugh A级)患者200例,1:1随机分层接受TACE-C-R或单纯TACE。
主要发现
- ≥3级治疗相关不良事件:TACE-C-R组74.5%(70/94),单纯TACE组22.3%(23/103)。
- 最常见≥3级治疗相关不良事件为AST升高(TACE-C-R组30.9% vs 单纯TACE组12.6%)和ALT升高(24.5% vs 13.6%)。
关键数值与推荐
- 主要终点为复合标准PFS(RECICL v5进展、一过性Child-Pugh C级恶化或TACE失败/难治)。
- 卡瑞利珠单抗200 mg每3周一次,阿帕替尼250 mg每日一次。
临床怎么用
- 对于不可切除且肝功能Child-Pugh A级的HCC患者,可考虑TACE联合卡瑞利珠单抗及阿帕替尼以延长PFS。
- 联合治疗≥3级肝酶升高发生率较高,需密切监测肝功能。
局限性
- 总生存数据尚未成熟,需进一步随访。
- 为II期试验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Transarterial chemoembolization (TACE) alone has shown limited efficacy in improving survival among patients with unresectable hepatocellular carcinoma (HCC). This phase II trial compared TACE combined with camrelizumab (anti-PD-1 antibody) and rivoceranib (vascular endothelial growth factor receptor 2 inhibitor) versus TACE in unresectable HCC. METHODS: Patients with unresectable HCC (Barcelona Clinic Liver Cancer stage A to C without extrahepatic metastases) and Child-Pugh class A liver function were randomly assigned (1:1), stratified by macrovascular invasion, previous tyrosine kinase inhibitor treatment, and number of previous TACE procedures, to receive TACE combined with camrelizumab (200 mg once every 3 weeks) and rivoceranib (250 mg once daily; TACE-C-R) or TACE alone. The primary end point was progression-free survival (PFS) per composite criteria (progression per Response Evaluation Criteria in Cancer of the Liver version 5, transient deterioration to Child-Pugh class C, or TACE failure or refractoriness) in the intention-to-treat population. RESULTS: Between December 28, 2020, and October 29, 2023, 200 patients were randomly assigned (100 in each group). Median PFS per composite criteria was significantly longer with TACE-C-R than with TACE (10.8 months [95% CI, 8.8 to 13.7] v 3.2 months [95% CI, 2.4 to 4.2]; hazard ratio, 0.34 [95% CI, 0.24 to 0.50], P < .001). Grade ≥3 treatment-related adverse events occurred in 74.5% (70 of 94) of patients with TACE-C-R and 22.3% (23 of 103) of patients with TACE, with the most common being increased AST (29 [30.9%] and 13 [12.6%]) and increased ALT (23 [24.5%] and 14 [13.6%]). CONCLUSION: The addition of camrelizumab and rivoceranib to TACE showed statistically significant improvement in PFS for patients with unresectable HCC, with a manageable safety profile. Follow-up for further overall survival analysis is ongoing.
引用
- Zhu HD, Fan WJ, Zhao C, et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026. PMID: 41734362. doi:10.1200/JCO-25-01796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。